Industry finance reports show increased capital flows into biotech during the J.P. Morgan Healthcare Conference, with new funds announced and deal activity accelerating. BioCentury flagged multiple fund launches and conference‑week financings; market movers lists highlighted companies that posted sharp single‑day moves during JPM (ImmunityBio among top gainers). The data point to concentrated investor attention on select therapeutic modalities (cell therapy, oncology, diagnostics) while competition for capital remains uneven across subsectors.